# ImpriMed, Inc.

> ImpriMed is a Palo Alto-based precision medicine company using live-cell drug sensitivity testing and AI to predict how individual cancer patients - starting with dogs and cats - will respond to specific chemotherapy drugs. Founded in 2017 by Stanford engineering PhDs Sungwon Lim and Jamin Koo, ImpriMed serves a network of 250+ veterinary oncologists and is expanding its platform into human blood cancers and pharma CRO services.

- **Founded:** 2017
- **Headquarters:** Palo Alto, California, United States
- **Founders:** Sungwon Lim (Co-Founder & CEO), Jamin Koo (Co-Founder & CTO)
- **Team size:** ~45
- **Products:** Personalized Prediction Profile, Immunophenotyping & Flow Cytometry, PARR (Clonality Testing), MDR1 Genotyping, Digital Cytology
- **Notable:** Raised $23M Series A led by SBVA in December 2023., Peer-reviewed publication in Veterinary and Comparative Oncology validating ex vivo drug sensitivity plus AI for canine lymphoma chemo response prediction., Network of 250+ veterinary oncologists adopting the platform across 40 U.S. states.

## Products & services

- **Personalized Prediction Profile** — AI-driven drug response prediction for canine lymphoma and leukemia patients, built from ex vivo live-cell sensitivity testing on the patient's own cancer cells.
- **Immunophenotyping & Flow Cytometry** — Lab diagnostic services that classify cancer subtypes to guide treatment decisions.
- **PARR (Clonality Testing)** — PCR for antigen receptor rearrangements used to confirm lymphoma diagnosis.
- **MDR1 Genotyping** — Genetic test for multidrug sensitivity in dogs, flagging breeds at risk of adverse drug reactions.
- **Digital Cytology** — Digital pathology service supporting remote diagnostic interpretation.
- **xCellSense (Human Oncology)** — In-development platform extending live-cell drug response prediction to human blood cancer patients.
- **Pharma CRO Services** — Drug discovery and development partnerships using ImpriMed's high-throughput live-cell testing platform.

## Achievements

- Raised $23M Series A led by SBVA in December 2023.
- Peer-reviewed publication in Veterinary and Comparative Oncology validating ex vivo drug sensitivity plus AI for canine lymphoma chemo response prediction.
- Network of 250+ veterinary oncologists adopting the platform across 40 U.S. states.
- Expansion into human blood cancer prediction with the xCellSense platform.
- Dual presence in Palo Alto and Seoul, bridging Silicon Valley and Korean biotech ecosystems.

## Latest updates

- **2023-12** — Closed $23M Series A led by SBVA to expand drug response prediction technology into human oncology and grow the team.
- **2021-10** — Launched new diagnostic services for canine lymphoma including immunophenotyping and clonality testing.
- **2021-02** — Published machine-learning study in Veterinary and Comparative Oncology predicting chemo response in canine lymphoma.

## Links

- Website: https://imprimedicine.com
- LinkedIn: https://www.linkedin.com/company/imprimed-inc
- Twitter/X: https://twitter.com/imprimedicine
- Facebook: https://www.facebook.com/imprimedicine

---

Profile page: https://yespress.io/imprimed-inc
Published by YesPress — https://yespress.io
Last updated: 2026-06-29